NEXUS Aortic Arch Stent Graft System
Endospan , Ltd. · Decision date Apr 2, 2026
What did the FDA approve?
FDA approved PMA P250033 for the NEXUS Aortic Arch Stent Graft System from Endospan, Ltd. The approval statement describes the device as indicated for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair who have appropriate anatomy.
The database entry does not include a supplement type or supplement reason, so no changed item or modification to an earlier PMA is identified. The statement reports the device's indicated purpose but does not provide independent proof of safety or clinical effectiveness. Specific information absent from the record includes any prior PMA relationship, clinical data, or anatomical criteria defining appropriate anatomy.
FDA approval order statement
for the NEXUS Aortic Arch Stent Graft System. This device is indicated for the endovascular treatment of chronic dissections involving the aortic arch in patients who are at high risk for open surgical repair and who have appropriate anatomy
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250033
- Regulatory pathway
- Premarket approval application
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- Decision code
- APPR
- Decision date
- Apr 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.
- Applicant
- Endospan , Ltd.
- Product code
- SDZ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250033 received
Application receipt date recorded by FDA.
P250033 · FDA decision
APPR
P250033/S001 · Related supplement
NEXUS Aortic Arch Stent Graft System
P250033/S002 · Related supplement
NEXUS Aortic Arch Stent Graft System
P250033/S004 · Related supplement
NEXUS Aortic Arch Stent Graft System
Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NEXUS Aortic Arch Stent Graft SystemP250033/S001 | Endospan , Ltd. | PMA supplement | May 20, 2026 | FDA |
NEXUS Aortic Arch Stent Graft SystemP250033/S002 | Endospan , Ltd. | PMA supplement | Jul 24, 2026 | FDA |
NEXUS Aortic Arch Stent Graft SystemP250033/S004 | Endospan , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endospan , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Alta Meadows Rd., Alta, WY, 83414
Sources and methodology
- Original FDA record: P250033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

